Organogenesis Holdings (ORGO) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with ORGO. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

Figures here are tied to the asOf date; verify live numbers in the latest filings before acting. Trailing revenue and the ~0.3x price-to-sales ratio still include the strong second half of 2025, so they flatter a business now running at roughly $40-50 million a quarter; on 2026 consensus revenue the stock trades closer to 0.7x sales. With losses and no forward earnings, the value hinges on whether the wound care market normalizes, how much more dilution is needed, and whether ReNu is approved. Do not treat any of this as a price target or a recommendation.

For the fiscal year ending Dec 2026, the 2 analysts publishing estimates on ORGO expect earnings of -$1.38 per share and revenue of $196.1 million (-65%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Organogenesis Holdings next reports on November 5, 2026, which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ORGO do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Organogenesis Holdings can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are CMS reimbursement reset and market adaptation, ReNu BLA in knee osteoarthritis, Product breadth, clinical evidence, and installed clinician base. The risk cited most often against it is the dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform has already cut quarterly revenue by more than half and forced two rounds of lower guidance.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ORGO is it a buy page. This page deliberately stops at the numbers.